Physician profile
Mohammad Kashef
NPI 1306134911
$11,688.46
in general payments reported to CMS, 2019-2025
32 companies · $648 in 2025
The $648 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $1,406 · 2021: $2,488 · 2022: $2,457 · 2023: $1,778 · 2024: $1,445 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,870.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,502.97 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,290.37 | 2019-2025 | |
| Medtronic, INC. | $1,254.87 | 2022-2025 | Corevalve Evolut R, Venaseal |
| Amgen INC. | $1,038.18 | 2019-2024 | Repatha |
| Cardiovascular Systems INC. | $823.77 | 2019-2023 | Diamondback Coronary |
| Pfizer INC. | $811.43 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $800.53 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $629.78 | 2019-2025 | Camzyos, Eliquis |
| Baylis Medical Company INC | $579.89 | 2021 | |
| Boston Scientific Corporation | $533.56 | 2020-2025 | Watchman Access System, Patientcare Link, Lux-Dx Insertable Cardiac Monitor |
| Abbott Laboratories | $429.21 | 2022-2024 | Mitraclip, Diamondback Coronary, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.64 | 2019-2024 | Jardiance |
| Penumbra, INC. | $247.54 | 2022-2025 | Indigo System |
| Merck Sharp & Dohme LLC | $184.82 | 2021-2024 | Verquvo |
| Edwards Lifesciences Corporation | $180.25 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $152.30 | 2019-2020 | |
| Novo Nordisk INC | $111.16 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $105.25 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $99.21 | 2020-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $92.54 | 2021-2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $83.40 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $79.60 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.03 | 2019-2024 | Lifevest |
| Philips North America LLC | $67.77 | 2024 | (Ao0) Igt Devices Intracardiac |
| Alnylam Pharmaceuticals INC. | $67.23 | 2019-2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $52.50 | 2025 | |
| Altathera Pharmaceuticals LLC | $30.98 | 2023-2024 | Sotalol Hydrochloride |
| Heartflow, INC. | $29.31 | 2022 | |
| W. L. Gore & Associates, INC. | $28.95 | 2022 | |
| Glaxosmithkline, LLC. | $19.99 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Lundbeck LLC | $17.43 | 2019 | |
| Esperion Therapeutics, INC. | $17.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Kashef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.